Synedgen Welcomes New Board Member Paul Grint
Recognized Industry Leader in Pharmaceutical Development
December 15, 2014—Synedgen is pleased to announce the appointment of Paul C. Grint, M.D. to our Board of Directors.
Dr. Grint, who serves as Chief Medical Officer at Regulus Therapeutics Inc., has more than two decades of experience in biologics and small molecule pharmaceutical development, including the successful commercialization of numerous commercial products in oncology, infectious disease and immunology.
Prior to joining Regulus, Dr. Grint was President of Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, Inc., and was responsible for the oversight of anti-infective product development. Prior to joining Cerexa, Dr. Grint served as Senior Vice President at Forest Research Institute, Inc., a subsidiary of Forest Laboratories, Inc. Previously he has served as the Chief Medical Officer of Kalypsys, Inc., Chief Medical Officer and Senior Vice President of Zephyr Sciences, Inc. Dr. Grint served as Vice President of Clinical Research and Development of Pfizer La Jolla, IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation.
Dr. Grint received his bachelor’s degree from St. Mary’s Hospital in London and his medical degree from St. Bartholomew’s Hospital Medical College at the University of London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies
Dr. Grint serves as a Member of the Scientific Advisory Board at Tobira Therapeutics Inc. and has previously been a Director of Numira Biosciences, Inc. and Illumina Inc. He served as Chairman of the Advisory Council of the Keck Graduate Institute.
“We are honored to add Paul to our Board,” commented Synedgen president Shenda Baker. “His experience compliments our existing Board, and his expertise in product development and strategic planning will be an important asset for Synedgen as we advance our therapeutic pipeline.”